Generic Product News (September 2017)

Pharmacy Times, September 2017 Immunization, Volume 83, Issue 9

Read about the new generic products featured in September.

Zydus Pharmaceuticals (USA) Inc

COMPARE TO: Lialda (Shire)

INDICATION: Zydus has launched Mesalamine Delayed-Release Tablets, 1.2 g, the first AB-rated equivalent to Lialda. The drug is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis, and for the maintenance of remission of ulcerative colitis.

DOSAGE FORM: Delayed-release tablet, 1.2 g

FOR MORE INFORMATION: zydususa.com

DESONIDE CREAM, 0.05%MARKETED BY: Glenmark Pharmaceuticals Inc, USA

COMPARE TO: Desonide Cream, 0.05% (Perrigo Company plc)

INDICATION: The FDA has approved Glenmark Pharmaceuticals’ generic version of Desonide Cream, 0.05%, to treat inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses.

DOSAGE FORM: Topical

FOR MORE INFORMATION: glenmarkpharma.com

SEVELAMER CARBONATE TABLETS, 800 MGMARKETED BY: Aurobindo Pharma USA

COMPARE TO: Renvela (Genzyme Corporation)

INDICATION: The FDA has approved Aurobindo’s Sevelamer Carbonate Tablets, 800 mg, the generic version of Renvela, indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

DOSAGE FORM: Tablet, 800 milligrams

FOR MORE INFORMATION: aurobindo.com

ESTRADIOL VAGINAL INSERTSMARKETED BY: Teva Pharmaceutical Industries Ltd

COMPARE TO: Vagifem (Novo Nordisk, Inc)

INDICATION: Teva has launched its generic version of Vagifem (estradiol vaginal inserts), 10 mcg, in the United States. Estradiol vaginal inserts are an estrogen indicated for the treatment of atrophic vaginitis due to menopause.

DOSAGE FORM: Vaginal insert, 10 mcg

FOR MORE INFORMATION: tevapharm.com